May 7, 2026
11 min read
Written by: Dr. Roupen Odabashian, MD
Reviewed by: Dr. Roupen Odabashian, Hematology-Oncology Specialist
Disclaimer: Disclosure: Dr. Odabashian is the founder of MeducationAI, an AI-powered oncology board review platform. The clinical and policy recommendations in this article are based on peer-reviewed evidence and the AAMC framework. Internal links to MeducationAI are provided for illustrative purposes.
Table of Contents
The ABIM hematology board review process changes every year — and 2026 is no exception. New drug approvals, updated NCCN guidelines, and shifts in exam emphasis mean that fellows preparing for boards need a study strategy that reflects what's actually being tested now, not what was tested two years ago. If you're sitting for the ABIM hematology certification exam in 2026, this guide breaks down exactly what's changed and how to prepare.
Below, we cover the ABIM blueprint, the 2026 content changes you need to prioritize, new drugs and approvals fellows should master, and the study timeline that actually works.
TL;DR
The 2026 ABIM hematology board exam is a 4-hour, 200-question computerized test heavily weighted toward hemostasis/thrombosis (20–25%) and white cell/lymphoid disorders (20–25%).
Venetoclax-HMA combinations are now standard of care for older/unfit AML patients — expect multiple questions on mechanism, toxicity, and resistance.
New drugs to master include glofitamab (CD20-TcB for relapsed NHL), finerenone (sickle cell VOC reduction), and expanded CAR-T indications including anti-BCMA for myeloma.
Start board prep 6 months out using a phased approach: foundation reading (months 1–2), daily question bank practice (months 3–4), timed full-length exams (months 5–6), and a low-stress final polish week.
Guideline-aligned study tools like MeducationAI that weight questions to the ABIM blueprint are far more efficient than generic question banks.
The ABIM hematology certification exam is a computerized, single-session test lasting 4 hours, consisting of approximately 200 multiple-choice questions covering the full breadth of hematology. The exam uses a scaled scoring system (255–299 typically passing; exact cut-off varies). You need not only breadth but mastery of high-frequency topics.
Questions are integrated, scenario-based clinical vignettes that match real practice rather than isolated factoid recall. That's why rote memorization fails and integrated study — like structured board review strategies, question banks, and case-based learning — outperforms passive reading every time.
The ABIM releases a detailed Content Specification and Sample Examination on their website. Here's the approximate percentage breakdown by topic area for 2026:
Hemostasis & Thrombosis (20–25%): Bleeding disorders, VTE, anticoagulation, antithrombotic agents, DIC, thrombotic microangiopathies.
Red Cell Disorders (15–20%): Anemia workup, iron metabolism, hemolysis, thalassemia, sickle cell disease, G6PD.
White Cell & Lymphoid Disorders (20–25%): Leukemias (AML, CML, ALL), lymphomas (Hodgkin, NHL), myelodysplasia, immune deficiencies.
Malignancy & Chemotherapy (15–20%): Solid tumors (lung, breast, GI, ovarian), targeted therapies, immunotherapy toxicities.
Platelet & Bone Marrow Disorders (10–15%): ITP, TTP, DIC, aplastic anemia, myeloproliferative neoplasms.
Transfusion Medicine (5–10%): Blood product selection, alloimmunization, hemolytic transfusion reactions, massive transfusion protocols.
Important: These percentages shift slightly year to year. Hemostasis and thrombosis are heavily weighted (anticoagulation management is always tested), so allocate study time accordingly.
Every year, ABIM updates the exam blueprint and adjusts emphasis based on emerging evidence and practice changes. Here are the most significant 2026 updates you need to know for your ABIM hematology board review:
Venetoclax combined with hypomethylating agents (HMA) is now the standard of care for newly diagnosed AML in patients over 65 or unfit for intensive chemotherapy, replacing older supportive-care-only approaches. Expect multiple board questions on this regimen's mechanism (BCL-2 inhibition), response rates (~55–65% CR + CRi), toxicity profile (tumor lysis syndrome requiring careful prophylaxis, infection risk, cytopenias), and emerging resistance mechanisms including TP53 mutations. A typical board-style vignette will present an elderly AML patient on venetoclax-azacitidine who develops a complication and ask you to identify the cause and management.
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated a roughly 25% reduction in annualized vaso-occlusive crisis (VOC) rate versus placebo in recent clinical trials. It reduces kidney inflammation and endothelial dysfunction, emerging as adjunctive therapy alongside hydroxyurea, transfusion, and analgesics. The key caution is hyperkalemia risk requiring close monitoring. Boards will likely test your knowledge of new therapeutic options for sickle cell VOC management — finerenone is the newest addition to the toolkit.
Glofitamab is an anti-CD20/anti-CD3 T-cell bispecific (TcB) antibody that bridges T cells to malignant B cells, achieving high response rates in relapsed/refractory B-cell NHL including ibrutinib-resistant cases. The critical toxicities to know are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) — these are not the same as CAR-T toxicities in severity but require similar monitoring frameworks. Compared to CAR-T, glofitamab offers faster time to response and is available as an off-the-shelf therapy without the manufacturing delay.
CAR-T is no longer experimental — by 2026, boards assume familiarity with T-cell engineering, costimulatory domains (CD28 vs. 4-1BB), approved indications (relapsed/refractory B-ALL, DLBCL now second-line standard, CLL), and toxicity management including CRS grading and IL-6 blockade with tocilizumab. Anti-BCMA CAR-T for multiple myeloma is now FDA-approved, and boards will test patient selection criteria including functional baseline and disease burden.
The exam increasingly tests your understanding of PD-L1 expression levels and how they predict immunotherapy response. The algorithm you must know: PD-L1 ≥50% means checkpoint inhibitor monotherapy (pembrolizumab) is first-line and superior to chemo; PD-L1 1–49% means chemotherapy plus checkpoint inhibitor is preferred; PD-L1 <1% means chemotherapy backbone is often needed with or without immunotherapy. This is no longer optional knowledge — boards test whether you can apply this algorithm.
The ABIM exam closely follows NCCN Clinical Practice Guidelines updated annually in January–February. For 2026, key updates include: AML (venetoclax-HMA as standard of care for older/unfit patients), CML (ponatinib increasingly recognized for T315I mutation), lymphoma (glofitamab and other TcBs in relapsed/refractory algorithms), and breast cancer (escalating CDK4/6 inhibitor use). You must be familiar with the most recent NCCN guidelines — boards test what's considered standard of care now, not what was standard two years ago. If you need a structured approach to reading these guidelines, our guide on how to read the NCCN guidelines breaks down the process step by step.
Hematology-oncology fellows should start ABIM board prep at least 6-months before exam day, following a phased approach that builds from foundational reading to timed exam simulation. Here is the timeline that works:
The goal during months 1–2 is to understand core concepts, not memorize facts. Read the NCCN guidelines cover-to-cover for hematologic malignancies (AML, CML, ALL, lymphomas, myeloma) and core hematology topics (hemostasis, red cell disorders). Work selectively through a reputable textbook (Williams Hematology or Hoffman's Clinical Hematology) on high-frequency topics. Build mind maps of interconnected topics — for example, a central node of "Acute Myeloid Leukemia" with branches for risk stratification, treatment algorithms, and new drug approvals. Supplement with expert-curated audio content: heme/onc podcasts are an efficient way to reinforce learning during commutes or downtime.
During months 3–4, aim for 30–50 questions per day from a hematology oncology question bank and review answers immediately afterward. Don't just ask "why is C right?" — ask "why is A wrong? What's the clinical pearl?" Track your performance by topic to identify weak areas: are you struggling with anticoagulation, lymphoma management, or transfusion medicine? Return to weak-area questions after 2 weeks using spaced repetition — they'll be harder than you remember.
By month 5, you should be sitting full-length, timed practice exams 2–3 times per week. Simulate real exam conditions: 4 hours, single session, no distractions, strict time management averaging about 1 minute per question. Review every missed question, even ones you "kind of understood" — that's often where exam vulnerabilities hide. Supplement with AI-generated flashcards built from your notes for rapid final-phase review.
The last two weeks before your exam are about consolidating, not cramming. Stop reading new guidelines, you should know them by now. Review weak-area questions only. Practice one timed block per day (not multiple blocks to avoid burnout). Prioritize sleep, exercise, and stress management. The burnout prevention strategies that serve you during fellowship are equally important during the final stretch of board prep.
The MeducationAI Question Bank is specifically aligned to the ABIM hematology blueprint, meaning questions are weighted by topic frequency (more hemostasis questions, more leukemia/lymphoma questions), explanations reference NCCN guidelines, primary literature, and PubMed links, and new drug approvals and 2026 guideline changes are incorporated into questions. Performance analytics show which blueprint areas you've mastered and which need focus. This is exponentially more efficient than randomly practicing generic questions.
Your fellowship clinic, consults, and conferences are board prep if you approach them strategically. Every patient encounter is an opportunity to reinforce board-relevant knowledge — here's how to capitalize on it.
When you see a patient with AML, actively quiz yourself: What's the risk stratification (cytogenetics, mutations, FLT3-ITD, TP53)? What's the treatment algorithm (intensive vs. venetoclax-HMA vs. selinexor)? How will you assess response (morphologic CR vs. CRi vs. PR, MRD monitoring)? Then review the NCCN guideline for that specific scenario. This integrates real patients with board content in a way that passive reading never can. Fellows who are managing their first AML patients can use each case as a structured learning opportunity.
When a case is presented at conference, pause and think like a board examiner: Would the exam ask about this diagnosis? What's the board-relevant pearl — not the rare finding, but the high-yield management decision? What would boards expect you to know about this disease? This mental framework transforms passive attendance into active board preparation.
MeducationAI's Learning Hub lets you upload your fellowship lecture PDFs, and the tool converts them into AI-generated flashcards (FSRS-based, optimized for spaced repetition), automatically generated quizzes, and mind map suggestions based on your course structure. This means your fellowship materials become your study materials with no duplication of effort.
By month 5 (about 6 weeks before your exam), you should transition to full-length timed exams as the core of your study plan. Here's the week-by-week approach that builds confidence without burning you out:
Weeks 6–4 before exam: One full-length timed exam per week. Review for 2–3 hours after each exam, focusing on weak areas.
Weeks 3–2 before exam: Two full-length exams per week (Monday and Thursday). Lighter review with a focus on confidence-building.
Week 1 before exam: One full-length exam early in the week to catch late vulnerabilities. Minimal review; focus on rest and managing test anxiety.
Final 3 days: Light review of weak areas only. No full exams. Prioritize sleep and stress management.
Most fellows who pass on their first attempt study for 6 months using a phased approach: 2 months of foundational reading, 2 months of daily question bank practice (30–50 questions per day), and 2 months of timed full-length practice exams. Starting earlier gives you time to identify and shore up weak areas without cramming.
The ABIM hematology certification exam pass rate for first-time takers is typically around 80–87%, according to ABIM published data. However, this means roughly 1 in 6 well-trained fellows still fails on the first attempt — usually due to poor study strategy rather than lack of knowledge.
Hemostasis and thrombosis (20–25% of the exam) and white cell/lymphoid disorders (20–25%) are consistently the highest-yield categories. Within these, anticoagulation management, AML treatment algorithms, and lymphoma classification are the most frequently tested subtopics. Allocate the majority of your study time to these areas first.
A question bank alone is not sufficient — but it is the single most important study tool. Pair it with NCCN guideline reading, clinical integration during fellowship rotations, and timed practice exams. The most effective approach combines a blueprint-aligned heme/onc question bank with structured review of missed questions.
Turn every clinic patient and conference case into a board prep opportunity by actively quizzing yourself on risk stratification, treatment algorithms, and guideline-based management. Upload your fellowship lecture materials to study tools like MeducationAI that convert PDFs into flashcards and quizzes. This eliminates the duplication of learning clinical medicine and studying for boards separately.
Ready to start your 2026 ABIM hematology board review?
Your board score depends on your study method, not your effort. Thousands of smart, hard-working fellows fail boards every year because they studied the wrong way or used the wrong tools. Don't be one of them.
Frequently Asked Questions
Who is this ABIM Hematology Board Review: What Changed in 2026 and How to Prepare article for?
This article is written for medical students, residents, fellows, and clinical educators looking for evidence-aligned guidance in oncology learning and board preparation.
Can this article replace clinical judgment or institutional policy?
No. This article is an educational resource and does not replace clinical judgment, institutional protocols, or specialty guideline updates.
How should I use this article for exam preparation?
Use it as a framework: review the key concepts, test yourself with practice questions, and pair your study with current guideline documents and physician-led teaching.
Dr. Roupen Odabashian, MD
Dr. Roupen Odabashian is a hematology-oncology specialist in Tucson, Arizona. He is currently practicing at the University of Arizona Health Sciences Center.
Full author profileJoin MeducationAI, the AI-powered medical education platform built for students across specialties, with personalized tutoring, smart study tools, and realistic clinical case simulations.
Get StartedShare this article
